Privia Health Group, Inc. (PRVA)
NEUTRAL基本面
62
价格
$21.03
市值
$2.70B
第一部分 · 这家公司值多少
概览
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$2.36B
最近12个月(截至2026/6/30)
净利润
$28M
最近12个月(截至2026/6/30)
自由现金流
-
股东权益合计
$737M
负债合计
$578M
流动比率
1.62
利息覆盖率
-
债务/EBITDA
0.20
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$19.19
当前价格
$21.03
安全边际
-9.6%
公允价值区间
$12.47 - $25.90
估算方法
估值指标
市盈率(P/E)
95.55
ROE
3.1%
市净率(P/B)
3.43
P/FCF
-
毛利率
-
ROIC
4.2%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
4.2%
WACC
8.9%
ROIC − WACC
-4.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过(13)
- EPS shows upward trend
- EPS CAGR 12.25%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 21.0%
- Analyst Consensus 88% Buy
- Earnings Surprise avg 3.9%
- Earnings Quality (OCF/NI) 4.66
- Share Dilution -2.6%
- Net Margin Trend 1.2% vs 0.8%
- Piotroski F-Score 6/9
未通过(8)
- Price CAGR -3.98%
- ROIC 4.2%
- P/B Ratio 3.43
- Operating Margin 1.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
不可用(7)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
信号混杂:部分领域需关注
盈利质量
高质量:盈利有现金流支撑
股权稀释
正在回购股份,对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Parth Mehrotra | CEO & Director | 46 |
| Mr. David Mountcastle CPA, MBA | Executive VP & CFO | 55 |
| Mr. Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 60 |
| Mr. Sarath Degala | Chief Operating Officer | - |
| Mr. Konda Mullapudi | Executive VP & CTO | - |
| Mr. Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | - |
| Ms. Dana Fields CPA | Chief Audit & Compliance Officer | - |
| Ms. Jenny Harding | Chief People Officer | - |
| Mr. Jay Stevens | Senior VP & Chief Growth Officer | - |
| Mr. Eric J. Beyer | Executive Vice President of Medical Groups | - |
审计风险
1
董事会风险
2
薪酬风险
3
股东权利风险
6
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for PRVA, sourced from Markets Gazette.
- 2/26/2026NEUTRALPrivia Health (PRVA) Q4 2025 Earnings Transcript
The financial market is currently awaiting the detailed transcript of Privia Health's (PRVA) Q4 2025 earnings call. While the specific content remains unavailable, investors will be keenly scrutinizing this document for clarity on the company's financial health and future trajectory. Earnings transcripts are vital as they provide direct insights from management discussions, detailing revenues, profits, operating margins, and crucially, future guidance. The current lack of concrete data keeps the stock in a state of anticipation, with market participants looking for signals regarding patient growth, geographical expansion, and cost management strategies. The stock's reaction will heavily depend on the tone and figures revealed once the full transcript is released.
via Markets Gazette